ACE、ACE/ACE2对胰腺癌的临床诊断价值初探

目的：探讨血清ACE、ACE2以及其比值对胰腺癌的临床诊断价值。方法：用ELISA方法检测15例胰腺癌患者、10例胰腺癌术后无复发患者、10例单纯CA199升高患者、10例胰腺炎患者及10例健康体检者血清ACE、ACE2、ACE/ACE2的含量，胰腺癌组分别与良性病变组和正常对照组比较。结果：胰腺癌组中ACE、ACE/ACE2分别为(275.340±247.042)、(0.482±0.398) pg/mL，相较胰腺癌术后无复发组、单纯CA199升高组、胰腺炎组和对照组明显升高，差异具有统计学意义(P<0.01)。CA199升高组ACE2水平为(628.343±114.383) pg/mL，明显低于对照组(948.89±496.498) pg/mL(P<0.05)。胰腺炎组ACE2为(515.078±157.815) pg/mL，显著低于对照组。但CA199升高组与胰腺炎组之间无统计学差异(P>0.05)。结论：血清ACE、ACE/ACE2在胰腺癌的诊断中有一定的临床应用价值，可为胰腺癌的诊断提供新的方法。

Diagnosis value of ACE,ACE/ACE2 as tumor markers in pancreatic cancer

Objective: To explore the clinical diagnostic value of serum ACE, ACE2, ACE/ACE2 in malignant tumors of digestive system.Methods: Serum levels of ACE, ACE2, ACE/ACE2 were detected by ELISA from 15 pancreatic cancer patients, 10 post-pancreatic operation patients, 10 CA199 elevated patients, 10 acute pancreatitis patients, and 10 healthy people, compared the pancreatic cancer group with the benign pancreatic disease and healthy group respectively.Results: ACE, ACE/ACE2 serum levels (275.340±247.042), (0.482±0.398) pg/mL] in pancreatic cancer group were signiifcantly higher than benign pancreatic disease group and healthy people (P<0.01). ACE2 in
CA199 elevated group (628.343±114.383) pg/mL and acute pancreatitis patients (515.078±157.815) pg/mL were lower than healthy people (948.89±496.498) pg/mL (P<0.05). But there were no statistical difference between elevated CA199 group and pancreatitis group (P>0.05).Conclusion: Serum ACE, ACE/ACE2 had clinical value in the diagnosis of pancreatic cancer, which can be provided new methods for the diagnosis of pancreatic cancer.